Trial · NCT07882654
A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS.
NCT07882654, Phase 2, Not yet recruiting, EktaH
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS. Trials, record NCT07882654. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07882654
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS.
- NCT number
- NCT07882654
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 31 participants, estimated
- Lead sponsor
- EktaH
- Conditions
- Obesity / Overweight, Obesity (BMI Equal to or >30)
- Interventions
Investigational product is a modified linoleic acid, named NKS-3. This non-caloric agent, synthetized from linoleic acid, is a fat taste receptors agonist, targeting CD36 with also an impact on GPR120, Placebo solution
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluate the effect of NKS-3 compared with placebo on the percent change in body weight from baseline (V0) to Day 90 (V2) in adults with obesity. | 90 Days of treatment. | The primary efficacy endpoint is the percent change in body weight from baseline (V0) to end of Treatment (V2, Day 90). The primary comparison will be the difference in percent body weight change between NKS-3 and placebo groups from baseline to day 90. |
| Secondary | To evaluate the effect of NKS-3 compared with placebo on oro-sensory sensitivity to linoleic acid | 90 Days. | To evaluate the effect of NKS-3 compared with placebo on oro-sensory sensitivity to linoleic acid, as assessed by the change in the linoleic-acid detection threshold using the 3-AFC method from baseline to Day 45 and Day 90. The secondary endpoint will be the oro-sensory detection thresholds (mmol/L) determined for each participant. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07882654
GET https://conductscience.org/api/trials/v1/NCT07882654/registered